产品名称 | NebuSelect™ Recombinant Human CD229/SLAMF3, Avi-His-tag |
---|---|
目录号 | NBL-242324 |
别名 | CD229/SLAMF3; SLAMF3; CD229; LY9; AI893573; Lgp100; T100 ; mLY9 |
外观 | see COA |
分子量 | Lys48-Lys454 |
CAS | N/A |
溶解度 | Water Soluble |
存储条件 | Short term 4℃; Long term -20℃. |
保存时间 | 2 years |
备注1 | Q9HBG7-1 |
备注2 |
目录号 | 规格 | 价格 | 库存状态 | |
NBL-242324-100ug | 100ug | Inquire | Inquire | |
NBL-242324-1mg | 1mg | Inquire | Inquire | |
NBL-242324-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Human CD229/SLAMF3, Avi-His-tag
Catalog#:
NBL-242324
Description:
NebuSelect™ Recombinant Human CD229/SLAMF3, Avi-His-tag(Cat#NBL-242324) is expressed in HEK293 with His tag and Avi tag at the C-Terminus.It contains Lys48-Lys454.
Species:
Human
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 47.7 kDa. Due to glycosylation, the protein migrates to 70-80 kDa based on Bis-Tris PAGE result.
Target Name:
CD229/SLAMF3; SLAMF3; CD229; LY9; AI893573; Lgp100; T100 ; mLY9
Target Information:
CD229 was strongly and homogeneously overexpressed on the PC of patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, MM, and PC leukemia. CD229 was particularly overexpressed on those PC showing an abnormal phenotype such as expression of CD56. Most importantly, CD229 was also highly expressed on those cells in the patients' BM displaying the phenotype of chemotherapy-resistant and myeloma-propagating cells.
Amino Acid Sequence:
Lys48-Lys454
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.